Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 14/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | USP1 | O94782 | 1/20 | 0.41 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3055540 | 0.88 | CD38 (0.62) | CD38CYP3A4KCNH2SLC2A1NR4A2 | |
| SCHEMBL3046223 | 0.87 | CD38 (0.64) | CD38CYP3A4KCNH2NR4A2 | |
| SCHEMBL3049143 | 0.87 | CD38 (0.61) | CD38CYP3A4KCNH2SLC2A1NR4A2 | |
| SCHEMBL3046044 | 0.87 | CD38 (0.61) | CD38CYP3A4KCNH2SLC2A1NR4A2 | |
| SCHEMBL3048795 | 0.86 | CD38 (0.56) | CD38CYP3A4KCNH2SLC2A1NR4A2 | |
| Hydrochloric Acid SCHEMBL3058772 | 0.86 | CD38 (0.63) | CD38CYP3A4KCNH2NR4A2 | |
| SCHEMBL8104854 | 0.86 | CD38 (0.55) | CD38CYP3A4KCNH2 | |
| SCHEMBL3048992 | 0.86 | CD38 (0.60) | CD38CYP3A4KCNH2MCHR1 | |
| SCHEMBL8105729 | 0.85 | CD38 (0.59) | CD38CYP3A4KCNH2SLC2A1NR4A2 | |
| SCHEMBL3050055 | 0.85 | CD38 (0.64) | CD38CYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420670-B2 | 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2013-04-16 | — | — | US | disclosed |
| US-20100222346-A1 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-09-02 | — | — | US | disclosed |
| EP-2178842-A2 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | Abbott GmbH & Co. KG (DE) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009024611-A2 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | ABBOTT GMBH & CO. KG (DE) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222346-A1 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | GDI2, GDI1, NQO2 | CD38 779/4885CYP3A4 31/4885KCNH2 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.